Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOGOS asthma trial
2023-505786-88-00Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of budesonide in asthma (3 arms), sponsored by AstraZeneca. Primary endpoints: Change from baseline in morning pre-dose trough FEV1 over 24 weeks and Rate of severe asthma exacerbations (pooled D5982C00007 and D5982C00008). Started Apr 2021; status: completed.
02
Drugs
budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on 2023-505786-88-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505786-88-00.